11 research outputs found
Caractérisation des lymphocytes T CD4 spécifiques au VIH chez les donneurs non-infectés
Les réponses des cellules T CD4 (Thelper, TH) jouent un rôle clé dans l'immunité antivirale. Cependant, celles générées par l'infection au VIH et les vaccins candidats sont variables. Des données chez la souris et l'humain suggèrent que des réponses TH antivirales peuvent être générées avant l'exposition à l'antigène spécifique par réaction croisée avec d'autres microorganismes et influencer les réponses TH ultérieures. Les réponses TH au VIH chez des individus séronégatifs seront investiguées et comparées à celles de sujets infectés. Une haute prévalence de réponses TH prolifératives au VIH a été observée chez des sujets VIH-. Gag montre une légère prédominance sur les autres protéines du VIH Env, Nef et Pol (33% des donneurs VIH- ont une réponse contre Gag >1% par test CFSE), mais qui diffère de l’immunodominance observée chez les donneurs VIH+. Malgré les réponses prolifératives plus petites chez les donneurs VIH-, des lignées cellulaires de TH spécifiques pour Gag ou Env ont pu être générées. Un marquage intracellulaire a validé leur spécificité et leurs fonctions montrant des réponses dominées par l'expression de TNF et CD40L comparativement à celles dérivées de donneurs VIH+ produisant beaucoup d’IFN-γ. L’affinité antigénique varie chez les sujets VIH-, mais peut être améliorée chez certains donneurs en optimisant la présentation antigénique. Une cartographie d’épitopes pour Env gp41 à identifier des épitopes reconnus par les TH. Les résultats montrent la présence de TH spécifiques au VIH chez une proportion de donneurs séronégatifs. Ces cellules pourraient influencer le développement de réponses vaccinales et spécifique au VIH durant l’infection aiguë.CD4+ T cell (Thelper, TH) responses play a key role in antiviral immunity. However, HIV-specific TH responses generated either by infection or by vaccine candidates are highly variable. Studies in mice and humans suggest that antiviral TH responses can be generated before exposure to the specific viral pathogen through cross-reactivity with other microorganisms These pre-existing responses may influence development of TH responses upon pathogen or immunogen exposure. We investigated HIV-specific TH responses in HIV-uninfected individuals (UD) and compared them to those of HIV-infected donors (HI). The prevalence of HIV-specific proliferative TH responses in UD was surprisingly high: 33% of UD had a robust Gag response >1% by CFSE assay. While Gag was more frequently targeted than the alternative HIV proteins Env, Nef and Pol, we did not observe the strong Gag immunodominance pattern seen in HI. Proliferative responses were overall lower in UD than HI, but strong expansion was occasionally observed. We derived Gag- and Env-specific short-term TH cell lines from UD and used intracellular staining to confirm their specificity and functions. TNF-α and CD40L dominated TH responses in UD lines, contrasting with HI lines that were robust IFN- producers. Functional affinity in UD was variable and could be improved in some subjects by optimization of antigen presentation. Gp41 epitope mapping identified peptides recognized by TH from UD. The results show that functional HIV-specific CD4 T cells exist in a substantial proportion of UD. Such pre-existing CD4 T cell could impact development of virus-specific TH responses at the time of acute HIV infection and influence responses to vaccine candidates
EXPLORATION DE L’EXPÉRIENCE D’ADULTES VICTIMES D’AGRESSION SEXUELLE QUI ONT REÇU DES SERVICES DANS LES CENTRES DÉSIGNÉS
L’objectif de cette étude vise à explorer l’expérience vécue par des femmes adultes victimes d’agression sexuelle dans les centres désignés. Cette étude a permis de faire ressortir certaines forces et faiblesses du modèle des centres désignés en plus de documenter les besoins les plus fréquents chez les victimes d’agression sexuelle. Les résultats obtenus suggèrent que malgré les progrès importants des dernières années dans l’aide apportée aux victimes d’agression sexuelle, il reste encore du travail à accomplir pour offrir à ces dernières des services qui répondent à l’ensemble de leurs besoins.This study aims to explore the experience of adult women victims of sexual abuse in Designated Centres. This study highlights some strengths and weaknesses of the Designated Centres model in addition to documenting the most common needs among sexual abuse victims. Despite significant progress in recent years in assisting victims of sexual abuse, results suggest that work is still needed to provide intervention services that target all their needs
Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells
<div><p>The identification and study of antigen-specific CD4 T cells, both in peripheral blood and in tissues, is key for a broad range of immunological research, including vaccine responses and infectious diseases. Detection of these cells is hampered by both their rarity and their heterogeneity, in particular with regards to cytokine secretion profiles. These factors prevent the identification of the total pool of antigen-specific CD4 T cells by classical methods. We have developed assays for the highly sensitive detection of such cells by measuring the upregulation of surface activation induced markers (AIM). Here, we compare two such assays based on concurrent expression of CD69 plus CD40L (CD154) or expression of OX40 plus CD25, and we develop additional AIM assays based on OX40 plus PD-L1 or 4-1BB. We compare the relative sensitivity of these assays for detection of vaccine and natural infection-induced CD4 T cell responses and show that these assays identify distinct, but overlapping populations of antigen-specific CD4 T cells, a subpopulation of which can also be detected on the basis of cytokine synthesis. Bystander activation had minimal effect on AIM markers. However, some T regulatory cells upregulate CD25 upon antigen stimulation. We therefore validated AIM assays designed to exclude most T regulatory cells, for both human and non-human primate (NHP, <i>Macaca mulatta</i>) studies. Overall, through head-to-head comparisons and methodological improvements, we show that AIM assays represent a sensitive and valuable method for the detection of antigen-specific CD4 T cells.</p></div
AIM markers identify overlapping populations of antigen-specific CD4 T cells.
<p>(A) Experiment protocol overview. Briefly, PBMCs were rested, then stimulated with antigen for 9-18hrs and stained for CD69, CD40L, OX40 and CD25 surface upregulation. (B) Example flow cytometry plots following 18-hr stimulation. (C) Quantification of data in (B) following a 9 hr (left) and 18 hr (right) antigen stimulation. CD69<sup>+</sup>CD40L<sup>+</sup> is shown in blue and OX40<sup>+</sup>CD25<sup>+</sup> in red. (D) Correlations between the two AIM assays following a 9 hr (left) and 18 hr (right) antigen stimulation. Data shown are background subtracted. Different antigens are indicated by color: HIV-1 Gag (purple), HIV-1 Env (orange), hCMV (dark blue) and HBV (green). R<sup>s</sup> = Spearman's Rank correlation co-efficient with associated <i>p</i> values. (E,F) Example flow cytometry plots demonstrating the co-expression of different AIM at 18 hr post-antigen stimulation for (E) OX40/CD25 expression on CD69<sup>+</sup>CD40L<sup>+</sup> CD4 T cells and (F) CD69/CD40L expression on OX40<sup>+</sup>CD25<sup>+</sup> CD4 T cells. Numbers shown in bottom row indicate percentage from parent gate. (G) Quantification of data in (E,F). Venn diagrams illustrate overlap between the two AIM marker<sup>+</sup> populations. All numbers represent mean percentages of AIM marker<sup>+</sup> cells from total CD4 T cells. For (B-G) n = 3–5 HIV-infected, hCMV-positive donors per antigen. (H,I) Example flow cytometry plot showing OX40/CD25 expression on cytokine-producing cells (ICS CD40L<sup>+</sup>IFNγ<sup>+</sup>, top panels), and cytokine production from OX40<sup>+</sup>CD25<sup>+</sup> cells (bottom panels), (<i>M</i>. <i>mulatta</i> PBMC). (I) Quantification of (H). (J) Detection of antigen-specific CD4 T cells by AIM vs. cytokine assays (<i>M</i>. <i>mulatta</i> PBMC). Cells from vaccinated animals were stimulated with BG505 antigen for a total of 21 hr with Brefeldin A added in the final 4 hrs. For H-J, n = 4 animals.</p
Comparing the OX40/CD25 and CD40L/CD69 AIM assays at their optimal time points.
<p>(A) A timeline of the assays’ setup and stimulation periods. (B) Example plots of OX40<sup>+</sup>CD25<sup>+</sup> (red) and CD40L<sup>+</sup>CD69<sup>+</sup> (blue) expression from human CD4 T cells when PBMC samples were unstimulated (UN), stimulated with peptides from HIV-Env, HIV-Gag, or hCMV, or stimulated with SEB as a positive control. Stimulation period was 9 hrs for the CD40L/CD69 assay and 18 hrs for the OX40/CD25 assay. Flow cytometry was gated as per <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0186998#pone.0186998.s001" target="_blank">S1 Fig</a> (C,D) Quantitation of signal response to each antigen after 9 hrs or 18 hrs of stimulation for the CD40L/CD69 and OX40/CD25 assays, respectively. n = 8 for Env and Gag groups, n = 10 for NS and hCMV groups. <i>P</i> values shown comparing signal in the Gag and hCMV stimulations to the unstimulated (UN) condition for both assays (Wilcoxon test). (E,F) Quantitation of response measured by fold-increase (antigen-stimulation signal divided by the signal in the unstimulated control) for each antigen after 9 or 18 hrs of stimulation for the CD40L/CD69 and OX40/CD25 assays, respectively. Dotted line is shown at a fold-increase of 2, indicating positive signal threshold. (G,H) Correlation between the signals detected by the two assays after computing the fold increase and background subtracted values. The different antigen stimulations are shown in orange (Env), purple (Gag), or dark blue (hCMV). R<sup>s</sup> = Spearman's Rank correlation coefficient with associated <i>p</i> values. For (E-H) n = 8 for Env and Gag groups, n = 10 for hCMV.</p
Treg cells in human PBMC.
<p>(A) Graph showing the frequency of Foxp3<sup>+</sup> Treg cells within the AIM<sup>+</sup> total CD4 population after 18 hrs of no stimulation (UN) or stimulation with tetanus peptide pool. (B) Increasing amounts of OX40<sup>+</sup>CD25<sup>+</sup> nTreg cells (Foxp3<sup>+</sup>Helios<sup>+</sup>) within the total CD4 T cell population in human PBMC in response to tetanus peptide pool stimulation. (C) Example plot of CD39 and Foxp3 expression of total CD4 T cells in an unstimulated human PBMC sample after 18 hrs of incubation at 37°C. (D) Venn diagram showing overlap between Foxp3 and CD39 expression on total CD4 T cells in unstimulated human PBMC (18 hrs at 37°C). Numbers shown are mean percentages; n = 12. (E) Example plots of signal detected using different combinations of AIM markers: OX40/CD25 in red, PD-L1/CD25 in orange, and PD-L1/OX40 in yellow. (F) Quantitation of AIM response via different marker combinations after stimulation with tetanus peptide pool. (G) Fold increase in signal for the different marker combinations (tetanus peptide pool stimulation response divided by the unstimulated condition). (H) Graph showing the percent of Foxp3<sup>+</sup> Treg cells within the AIM<sup>+</sup> total CD4 population in tetanus stimulated human PBMC where the AIM<sup>+</sup> population is defined by different combinations of markers. For A, B, E, F, G, and H, n = 12 donors. (I-K) PBMCs from 5 HIV-infected donors stimulated for 18 hrs with various HIV peptide antigens (Gag, Pol, and Nef). Antigen-specific CD4 T cells were identified by the upregulation of AIM markers and analyzed for the contributions of Helios<sup>+</sup>Foxp3<sup>+</sup> Tregs. n = 4–5 donors. (I) Example flow plots showing gating of AIM<sup>+</sup> populations, and subsequent identification of AIM<sup>+</sup> Foxp3<sup>+</sup>Helios<sup>+</sup> Tregs, following Gag stimulation (all plots from same donor). (J) Quantification of AIM<sup>+</sup> signal from the various marker combinations shown in the top panel of (I). (K) Quantification of Helios<sup>+</sup>Foxp3<sup>+</sup> Tregs within AIM<sup>+</sup> gates. Treg data shown only where antigen-specific responses were 2-fold over background (2–5 responses per antigen).</p
Treg cells in <i>M</i>. <i>mulatta</i> PBMC and lymph nodes.
<p>(A) Example gating scheme showing Foxp3 and Helios expression in OX40<sup>+</sup>CD25<sup>+</sup> GC Tfh (PD-1<sup>hi</sup>CXCR5<sup>hi</sup>) from <i>M</i>. <i>mulatta</i> lymph node. (B) Quantitation of the percent of Treg cells within the OX40<sup>+</sup>CD25<sup>+</sup> GC Tfh population after stimulation with antigen (BG505) (<i>M</i>. <i>mulatta</i> LN, n = 8 animals). (C) Quantitation of Treg cells within the OX40<sup>+</sup>CD25<sup>+</sup> total CD4 T cell population after stimulation with antigen (BG505) (<i>M</i>. <i>mulatta</i> PBMC, n = 9 animals). (D) Frequencies of OX40<sup>+</sup>CD25<sup>+</sup> nTreg cells (Foxp3<sup>+</sup>Helios<sup>+</sup>) within the total CD4 T cell population in <i>M</i>. <i>mulatta</i> PBMC compared between the unstimulated condition “UN” and in response to BG505. n = 7. (E) Example plot of CD39 and Foxp3 expression of unstimulated total CD4 T cells in <i>M</i>. <i>mulatta</i> PBMC after 18 hrs of incubation at 37°C. (F) Venn diagram demonstrating overlap between Foxp3 and CD39 expression on total CD4 T cells in <i>M</i>. <i>mulatta</i> PBMC after 18 hrs of incubation at 37°C without stimulation. Numbers shown are mean; n = 7. (G) Example gating scheme for detection of OX40 and 4-1BB (purple) or OX40 and CD25 (red) AIM<sup>+</sup> CD4 T cells in <i>M</i>. <i>mulatta</i> LN. (H) Fold-increase (signal from the antigen condition divided by the unstimulated condition) for the different marker combinations: OX40<sup>+</sup>CD25<sup>+</sup> (red) or OX40<sup>+</sup>4-1BB<sup>+</sup> (purple) (<i>M</i>. <i>mulatta</i> PBMC and LN, n = 15). (I) Comparison of Treg cell frequencies within the AIM<sup>+</sup> CD4 T cell population for the different marker combinations: OX40<sup>+</sup>CD25<sup>+</sup> (red) or OX40<sup>+</sup>4-1BB<sup>+</sup> (purple) (PBMC, incubated at 37°C for 18 hrs. n = 3).</p
Bystander activation by contaminants or non-TCR stimulation has limited impact on upregulation of AIM markers.
<p>(A,B) OX40/CD25 expression of PBMCs cultured in the presence of increasing amounts of LPS (25–2500 EU/ml), with an unstimulated (UN) and SEB condition as negative and positive control. (A) Example plots from a representative donor cultured with or without LPS. (B) Data shown as fold-increase (LPS/UN); n = 3 donors. (C) Experimental setup for transwell plate experiment, where antigen-exposed PBMCs were placed within the top well of a transwell plate, and antigen-naïve PBMCs were placed within the bottom well, with the two wells separated by a 0.4 μm pore-size permeable membrane. The cultures were then left unstimulated (UN) or stimulated with antigen (Ag) for 24 hours at 37°C. (D) Representative flow cytometry plot of the antigen-experienced PBMCs in the top well of the transwell plate (left column), the antigen-naïve PBMC in the bottom well of the transwell plate (middle column), and the antigen-naïve PBMC control in a separate plate (right column) after 24 hours in culture; with the unstimulated condition (UN) on the top row and antigen stimulated (Ag) on the bottom row. Gated on total CD4 T cells. (E) Quantification of the OX40<sup>+</sup>CD25<sup>+</sup> signal for the three culture conditions, unstimulated (UN) or stimulated with antigen (Ag). n = 3 antigen-naïve donors. (F) Diagram of the CD4 T cell line bystander activation experiment from panels G-K. Briefly, cell tracer-labeled (CellVue<sup>+</sup>) PBMCs were cocultured with an autologous CD4 T cell line at different ratios and stimulated with peptide antigens for 18 hr. (G,H) Example flow plots show the frequency of antigen-specific CD4 T cells CellVue<sup>+</sup> PBMCs in the top row compared to the total frequency of antigen-specific cells within the coculture (CD4 T cell line + CellVue<sup>+</sup> PBMCs) in the bottom row, at indicated ratios of CD4 T cell line and CellVue<sup>+</sup> PBMCs. Antigen-specific cells are identified as CD69<sup>+</sup>CD40L<sup>+</sup> (G) or OX40<sup>+</sup>CD25<sup>+</sup> (H) respectively. (I,J) Quantification of data shown in (G,H) for CD69/CD40L (I) and OX40/CD25 expression (J) respectively. The total frequency of antigen-specific cells in the culture (CD4 T cell line + CellVue<sup>+</sup> PBMCs) is indicated by grey bars; the frequency of CellVue<sup>+</sup> autologous CD4 T cells from PBMCs is indicated by the colored dots/lines. (K) Data shown as a relative change in the percentage of antigen-specific CD4 T cells from the CellVue<sup>+</sup> PBMCs at each ratio, compared to the PBMC alone condition. n = 3 independent experiments and donors, with HIV-Gag or hCMV pp65 peptide stimulation. Bars represent mean +/- SEM, dotted line at 100% (i.e. no change).</p
Identification of SARS-CoV-2-specific immune alterations in acutely ill patients
Dysregulated immune profiles have been described in symptomatic patients infected with SARS-CoV-2. Whether the reported immune alterations are specific to SARS-CoV-2 infection or also triggered by other acute illnesses remains unclear. We performed flow cytometry analysis on fresh peripheral blood from a consecutive cohort of (a) patients hospitalized with acute SARS-CoV-2 infection, (b) patients of comparable age and sex hospitalized for another acute disease (SARS-CoV-2 negative), and (c) healthy controls. Using both data-driven and hypothesis-driven analyses, we found several dysregulations in immune cell subsets (e.g., decreased proportion of T cells) that were similarly associated with acute SARS-CoV-2 infection and non-COVID-19-related acute illnesses. In contrast, we identified specific differences in myeloid and lymphocyte subsets that were associated with SARS-CoV-2 status (e.g., elevated proportion of ICAM-1+ mature/activated neutrophils, ALCAM+ monocytes, and CD38+CD8+ T cells). A subset of SARS-CoV-2-specific immune alterations correlated with disease severity, disease outcome at 30 days, and mortality. Our data provide an understanding of the immune dysregulation specifically associated with SARS-CoV-2 infection among acute care hospitalized patients. Our study lays the foundation for the development of specific biomarkers to stratify SARS-CoV-2-positive patients at risk of unfavorable outcomes and to uncover candidate molecules to investigate from a therapeutic perspective